VALCYTE (valganciclovir HCl)
CMV RETINITIS IN AIDS PATIENT·+3
ROCHE
Indication
Prevention of CMV disease after kidney transplantation
Prevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression. Read more about Prevention of CMV disease after kidney transplantation
27 drugs 24 manufacturers
Drugs that treat it
Common Prevention of CMV disease after kidney transplantation therapies.
VALCYTE (valganciclovir HCl)
CMV RETINITIS IN AIDS PATIENT·+3
ROCHE
VALGANCICLOVIR HCL
CMV RETINITIS IN AIDS PATIENT·+3
QUALITEST
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
DR.REDDY'S LAB
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
AHP
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
CAMBER PHARMACE
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
AUROBINDO PHARM
VALGANCICLOVIR HCL
CMV RETINITIS IN AIDS PATIENT·+3
ACTAVIS PHARMA,
VALGANCICLOVIR HCL
CMV RETINITIS IN AIDS PATIENT·+3
QUALITEST/PAR P
Filter & compare in the drug finder →Opens the drug finder with Prevention of CMV disease after kidney transplantation preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression.
In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R-)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms such as fever, malaise, cytopenias, and transaminitis, or progress to tissue-invasive disease involving the gastrointestinal tract, lungs, or allograft itself.
Prophylactic strategies are designed to inhibit viral DNA synthesis, thereby decreasing the risk of end-organ damage, acute or chronic graft rejection, and infection-associated mortality.
- nih.gov
Prevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms suc...
- fda.gov
Prevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms suc...
- lidsen.com
Prevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression
- nih.gov
In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms such as fever, malaise, cytopenias, and transaminitis, or progress to tissue-invasive disease involving the gastrointestinal tract, lungs, or allograft itself
- nih.gov
In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms such as fever, malaise, cytopenias, and transaminitis, or progress to tissue-invasive disease involving the gastrointestinal tract, lungs, or allograft itself
- nih.gov
Prophylactic strategies are designed to inhibit viral DNA synthesis, thereby decreasing the risk of end-organ damage, acute or chronic graft rejection, and infection-associated mortality
- lww.com
Prophylactic strategies are designed to inhibit viral DNA synthesis, thereby decreasing the risk of end-organ damage, acute or chronic graft rejection, and infection-associated mortality
Personalize your experience
Follow Prevention of CMV disease after kidney transplantation and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.